Recon: AbbVie, Voyager Partner on Gene Therapy for Alzheimer’s; Aimmune’s Peanut Allergy Drug Meets Goals in … – Regulatory Focus
Regulatory Focus |
Recon: AbbVie, Voyager Partner on Gene Therapy for Alzheimer’s; Aimmune’s Peanut Allergy Drug Meets Goals in …
Regulatory Focus Recon: AbbVie, Voyager Partner on Gene Therapy for Alzheimer’s; Aimmune’s Peanut Allergy Drug Meets Goals in Phase III. Posted 20 February 2018 | By Michael Mezher. Recon: AbbVie, Voyager Partner on Gene Therapy for Alzheimer’s; Aimmune’s Peanut … |
Regulatory Focus |
Recon: AbbVie, Voyager Partner on Gene Therapy for Alzheimer’s; Aimmune’s Peanut Allergy Drug Meets Goals in …
Regulatory Focus Recon: AbbVie, Voyager Partner on Gene Therapy for Alzheimer’s; Aimmune’s Peanut Allergy Drug Meets Goals in Phase III. Posted 20 February 2018 | By Michael Mezher. Recon: AbbVie, Voyager Partner on Gene Therapy for Alzheimer’s; Aimmune’s Peanut … |
|
Synthego Named One of World’s Top 10 Most Innovative Companies in Biotech by Fast Company
GlobeNewswire (press release) Synthego has played a critical role in unlocking the potential of CRISPR, advancing its ease of adoption and democratizing genome engineering. Starting as a provider of CRISPR reagents, Synthego has rapidly evolved into one of the world’s leading … |
Tampabay.com |
Doctors were wrong when they told her immunotherapy wouldn’t cure her cancer
Tampabay.com No one expected the four young women to live much longer. They had an extremely rare, aggressive and fatal form of ovarian cancer. There was no standard treatment. The women, strangers to one another living in different countries, asked their doctors … |